Earnings Release • Sep 12, 2018
Earnings Release
Open in ViewerOpens in native device viewer
| Informazione Regolamentata n. 0481-40-2018 |
Data/Ora Ricezione 12 Settembre 2018 19:32:04 |
MTA - Star | |
|---|---|---|---|
| Societa' | : | El.En. | |
| Identificativo Informazione Regolamentata |
: | 108375 | |
| Nome utilizzatore | : ELENN01 - Romagnoli |
||
| Tipologia | : REGEM; 3.1; 1.2; 2.2 |
||
| Data/Ora Ricezione | : | 12 Settembre 2018 19:32:04 | |
| Data/Ora Inizio Diffusione presunta |
: | 12 Settembre 2018 19:32:05 | |
| Oggetto | : | The Bod of El.En. releases the consolidated 2018 six months financial report |
|
| Testo del comunicato |
Vedi allegato.
1.2 2.2 3.1 REGEM
press release
Florence, September 12th, 2018 – The Board of Directors of El.En. SpA, leader on the laser market and listed on the STAR Segment of the Italian Stock Exchange, released today the six months consolidated financial report as of June 30, 2018.
In the first half of 2018 the growth of the El.En. Group continued with robust financial results that exceeded the sales increase forecast, highlighting the group's appreciation by the market. During the period under review, record consolidated revenues were achieved reaching 161 million of euro, up 12,4% compared to 1H 2017. EBITDA was 15,3 million euro, with an 9,6% margin on sales, slightly down compared to the 15,4 million euro of the previous financial year. EBIT amounted to 12,7 million euro, with a 7,9% on sales and with a decrease of 3% compared to 13,1 million euro in the same period of 2017. Net income for the Group was 7,4 million of euro with a 24% increase growth compared to 6,0 million in 1H 2017.
The general trends of our reference markets stays positive and continues to envisage significant growth opportunities for the group.
Medical and Industrial sector were almost aligned in the revenues growth rate of the period, both over 10%, slightly stronger in the medical second that showed revenues for 94 million of euro(vs. 83 million of euro in the corresponding period of 2017) marking a 13% increase on 2017; the industrial sector with sales for 67,0 million of Euro, (vs. 60 million in the first half of 2017) registered a 12% growth. As of geographical distribution, the most brilliant results in both sectors were obtained in Europe, where the revenues increase was just shy of 30%, while on the Italian and Extra-European markets the growth was close to 10%. Significant was the development of the
industrial sector in Europe, which highlights the Group's desire to acquire relevant market shares also outside Italy and China, to date the main outlet areas for the Group's products in the sector.
Andrea Cangioli, El.En. Spa' Managing Director said: "We are pleased by the financial results of this semester. We are growing also in not traditional markets for the Group, gaining market shares with our very innovative products. We are strengthening the manufacturing facilities and the global organization structure, with specific attention to Sales and Marketing. We are confident by this means to exploit even better in the future the opportunities surfacing both in the medical and industrial area, and to continue our growth progression."
In the medical sector all the market segments registered sales growth, mainly achieved in the most significant geographical areas.
As for new products, in the medical sector the semester was characterized by the launch of the Onda system, with its innovative approach of delivering microwave energy combined with a sophisticated cooling system for the effective and painless delivery of "Coolwaves" for body remodeling, cellulite and fat treatment. This system obtained the medical CE mark, which allows the marketing in EEC countries and in a few other States, in March 2018.
The renewed attention of the market towards non-invasive "body-shaping" treatments, a rapidly expanding application segment, initiated the process of designing Onda which marks the return of the Deka brand in the non-invasive body shaping market
Several new systems were launched on the market during the semester, or of which the authorization to sell in some countries has been achieved, thus expanding their marketing potential. Quanta System has added to its range of lithotripsy systems a 100W high power Holmium system, which has obtained FDA clearance, while the Japanese health ministry has authorized the sale of 60W Holmium systems for the removal of Urological kidney stones and of a Thulium 200W system for the treatment of BPH (Benign Prostatic Hyperplasia) with the ThuLep technique. As far as Holmium high power systems are concerned, these are very significant products, also in light of the OEM marketing through important international brands, which characterizes a relevant share of the group's sales in surgery. Also the Motus AY hair removal system, introduced by Deka on the market in the second quarter, has obtained the CE medical mark and FDA clearance that allows to start sales activities in the USA. In the same way, the new Punto system released by Deka for rejuvenation has obtained the CE medical mark.
In the industrial applications for manufacturing, the development of new products is in this period focused in the integration, within sheet metal cutting systems, of laser sources of increasingly high power 6, 8, 12 up to 15kW, power levels that allow increase in productivity and in maximum thickness effectively cut. In order to benefit of the productivity increase due to higher laser power, specific and complex configurations are needed for the system and its beam delivery tools, that our companies are able to design and implement based on the sophisticated know how gained and sedimented within the years of experience in the application.
Sales revenues in the industrial sector showed growth in all its segments, with a marked acceleration in the second quarter of the year. The cutting segment grew by 14%, also thanks to the Chinese joint ventures of Wuhan and Wenzhou where production capacity will increase in 2018 with a new location of Wuhan's facility and in 2019 with the new plant under construction in Wenzhou. The trend in the marking segment remains stable with a slight 0,9% increase, while the sources segment registered a growing success, with sales up 13,3% exploiting niche applications within the packaging, special processing and textile sectors. Sales trend in art conservation was positive, a business where the Group registers revenue but above all contributes to the conservation of the artistic heritage on a global scale.
Gross Margin of 1H 2018 was at 64.701 thousand euros, up 8,72% vs. 59.509 thousand euros as of June 30th, 2017, thanks to the increase in Sales volume. A decline in margins from 41,7% to 40,3% was registered in the first half of 2018, mostly due to a the less favorable mix of sales in the medical sector and to the reduction of certain grants to support R&D in the industrial sector.
EBITDA was equal to 15.349 thousand euro, substantially unchanged compared to the 15.469 thousand euro of 1H 2017. The decrease in EBITDA % margin, down from 10,8% to 9,6%, is the consequence of the reduction in the sales margin and the increase in structural operating costs aimed to sustain the further growth forecast, both in the medical and in the industrial sectors.
EBIT marked a positive balance of 12.731 thousand euros, down compared to 13.134 thousand euros as of June 30th, 2017, with a margin on sales decreasing to 7,9% from 9,2% in the same period of the previous year.
Pre tax income showed a positive balance of 13.090 thousand euro (10.881 thousand euro in 1H 2017), up 20,3% as an effect of the positive balance of financial management, less penalized than in the past by the trend of foreing exchange losses. The tax burden for the period showed a total expense of 3,7 million euros: the taxes for the period were calculated based on the best estimate of the expected tax rates for the year 2018. The tax rate for the period was approximately 28%, highet than 26% recorded in the same period of last year.
Net profit for the Group. The first half of 2018 ended with a net income for the Group of 7.452 thousand euros, a 24% increase compared to 6.010 thousand euros in 1H 2017.
The net financial position of the Group remains firmly positive even though declining by roughly 19 million of euros in the period to around 66,0 million euros, compared to 84,5 million euros as of December 31st, 2017. The cash absorption for the period was due to several factors: distribution of dividends totaling 8,4 million of euro; investments in fixed assets of 9,4 million, of which almost 1 million of euro for investments in plants for existing factories and 6,7 million of euro for the purchase, construction and equipment of new production facilities in Calenzano, Torre Annunziata, Jena, Vicenza and Wenzhou, (part of a larger investment plan aimed at expanding production capacity to serve the growing demand, for a total expected amount of about 28 million in the years 2018- 2019).
The increase in net working capital was the most significant cash usage of the period, as effect of the growth and in preparation for the fastest expected growth. The most significant changes were recorded in the Chinese companies, in Quanta System and in El.En.
Financial results for the first half exceeded the revenue growth guidance, with an increase of 12,5% vs. the forecast of 10%; while they recorded a delay with respect to the expected growth in EBIT income, which remained positive at 7,9% of revenues and decreased by 3% compared to the first half of 2017.
We continue to go through a favorable phase of our markets, we therefore believe we can reach and exceed the forecast of 10% in annual revenue growth, and we can achieve at the end of the year, in presence of a further acceleration in revenues, 10% EBIT growth.
The manager in charge of preparing the corporate accounting records, Enrico Romagnoli, declares, pursuant to paragraph 2, article 154-bis of the Consolidated Finance Law, that the accounting disclosures provided in this document correspond to the accounting records, books and entries.
As required by Consob, the Half yearly report as of June 30th, 2018 will be available for the public at our premises in Calenzano, at Borsa Italiana SpA, on our website www.elengroup.com from September 12, 2018 in section "Investor Relations / Documenti Finanziari / Relazioni e Bilanci / 2018" and on authorized storage website .
On Thursday, September 13th, 2018 at 15:00 CET (14:00 GMT) (9:00 EST), EL.EN. Spa will hold a conference call with the financial community, to discuss the financial results of the Group. You can dial the following numbers: from Italy +39 02 8058811, from UK +44 121 2818003, from USA +1 718 7058794. Before the conference call, you can download the presentation slides from the Investor Relations page of the El.En. website: http://www.elengroup.com/it/investorrelations/presentazioni
El.En., an Italian company, is the parent of a high-.tech industrial group operating in the optoelectronics sector. Based on proprietary technology and multidisciplinary know-how, the El.En Group manufactures laser sources (gas, semiconductor, solid-state and liquid) and innovative laser systems for medical and industrial applications. The El.En. Group is the laser market leader in Italy and among the top operators in Europe. It designs, manufactures and sells worldwide:
- Medical laser equipment used in dermatology, cosmetics, physiotherapy, dentistry and gynecology;
- Industrial laser systems for applications ranging from cutting, marking and welding metals, wood, plastic and glass to decorating leather and textiles and restoring/conserving artwork;
- Laser systems for scientific research
EL.EN has been listed on the Star (MTA) of Borsa Italiana. Its market floatation is approximately 41% and its market capitalization amounts to Euro 490 million.
Cod. ISIN: IT0005188336 Sigla: ELN Negoziata su MTA Mkt cap.: 490 milioni di euro Cod. Reuters: ELN.MI Cod. Bloomberg: ELN IM
For further information:
Investor Relator Enrico ROMAGNOLI - [email protected] Tel. +39 055 8826807
Financial Communication, IR and Press Office Bianca FERSINI MASTELLONI - [email protected] Paolo SANTAGOSTINO - [email protected] Silvia MARONGIU - [email protected] Tel. +39 06-69923324
| Income Statement | 30/06/2018 | Inc % | 30/06/2017 | Inc % | Var. % |
|---|---|---|---|---|---|
| Revenues | 160.637 | 100,0% | 142.877 | 100,0% | 12,43% |
| Change in inventory of finished goods and WIP | 10.411 | 6,5% | 5.208 | 3,6% | 99,90% |
| Other revenues and income | 1.539 | 1,0% | 1.661 | 1,2% | -7,36% |
| Value of production | 172.587 | 107,4% | 149.746 | 104,8% | 15,25% |
| Purchase of raw materials | 107.046 | 66,6% | 79.766 | 55,8% | 34,20% |
| Change in inventory of raw material | (11.674) | -7,3% | (237) | -0,2% | 4832,67% |
| Other direct services | 12.514 | 7,8% | 10.708 | 7,5% | 16,87% |
| Gross margin | 64.701 | 40,3% | 59.509 | 41,7% | 8,72% |
| Other operating services and charges | 21.243 | 13,2% | 17.977 | 12,6% | 18,16% |
| Added value | 43.458 | 27,1% | 41.532 | 29,1% | 4,64% |
| Staff cost | 28.109 | 17,5% | 26.062 | 18,2% | 7,85% |
| EBITDA | 15.349 | 9,6% | 15.469 | 10,8% | -0,78% |
| Depreciation, amortization and other accruals | 2.618 | 1,6% | 2.335 | 1,6% | 12,13% |
| EBIT | 12.731 | 7,9% | 13.134 | 9,2% | -3,07% |
| Net financial income (charges) | 474 | 0,3% | (2.204) | -1,5% | |
| Share of profit of associated companies | (109) | -0,1% | (49) | 0,0% | 123,17% |
| Other non-operating income (charges) | (6) | 0,0% | 0 | 0,0% | |
| Income (loss) before taxes | 13.090 | 8,1% | 10.881 | 7,6% | 20,30% |
| Income taxes | 3.681 | 2,3% | 2.824 | 2,0% | 30,37% |
| Income (loss) for the financial period | 9.409 | 5,9% | 8.057 | 5,6% | 16,77% |
| Net profit (loss) of minority interest | 1.957 | 1,2% | 2.047 | 1,4% | -4,40% |
| Net income (loss) | 7.452 | 4,6% | 6.010 | 4,2% | 23,99% |
| Statement of financial position | 30/06/2018 | 31/12/2017 | Variation |
|---|---|---|---|
| Intangible assets | 4.333 | 4.259 | 74 |
| Tangible assets | 46.631 | 39.178 | 7.454 |
| Equity investments | 3.464 | 3.587 | -123 |
| Deferred tax assets | 5.837 | 6.269 | -432 |
| Other non-current assets | 12.475 | 12.371 | 104 |
| Total non current assets | 72.740 | 65.664 | 7.076 |
| Inventories | 88.574 | 66.567 | 22.007 |
| Accounts receivable | 84.355 | 80.445 | 3.910 |
| Tax receivables | 10.910 | 8.942 | 1.968 |
| Other receivables | 13.539 | 13.939 | -400 |
| Financial instruments | 1.975 | 2.036 | -62 |
| Cash and cash equivalents | 75.299 | 97.351 | -22.052 |
| Total current assets | 274.652 | 269.281 | 5.371 |
| Total Assets | 347.393 | 334.945 | 12.447 |
| Share capital | 2.509 | 2.509 | 0 |
| Additional paid in capital | 38.594 | 38.594 | 0 |
| Treasury stock | 0 | 0 | 0 |
| Other reserves | 91.693 | 98.411 | -6.718 |
| Retained earnings / (accumulated deficit) | 50.502 | 35.173 | 15.329 |
| Net income / (loss) | 7.452 | 15.634 | -8.183 |
| Group shareholders' equity | 190.749 | 190.321 | 428 |
| Minority interest | 15.573 | 13.975 | 1.598 |
| Total shareholders' equity | 206.322 | 204.296 | 2.026 |
| Severance indemnity | 4.390 | 4.217 | 174 |
| Deferred tax liabilities | 1.501 | 1.483 | 18 |
| Reserve for risks and charges | 3.855 | 3.797 | 59 |
| Financial debts and liabilities | 6.169 | 5.875 | 293 |
| Total non current liabilities | 15.916 | 15.371 | 544 |
| Financial liabilities | 5.435 | 9.161 | -3.726 |
| Accounts payable | 75.285 | 63.257 | 12.028 |
| Income tax payables | 3.818 | 1.654 | 2.163 |
| Other current payables | 40.617 | 41.205 | -588 |
| Total current liabilities | 125.155 | 115.278 | 9.877 |
| Total Liabilities and Shareholders' equity | 347.393 | 334.945 | 12.447 |
| Cash flow statement | 30/06/18 | 30/06/17 |
|---|---|---|
| Operating activity | ||
| Income (loss) for the financial period | 9.409 | 8.057 |
| Depreciations | 2.091 | 1.911 |
| Share of profit of associated companies | 109 | 49 |
| Write-downs for impairment losses | 6 | 0 |
| Stock Options | 431 | 431 |
| Severance indemnity | 57 | 91 |
| Reserve for risks and charges | 59 | 77 |
| Bad debt reserve | (110) | (393) |
| Deferred tax assets | 460 | (176) |
| Deferred tax liabilities | 18 | (293) |
| Inventories | (22.007) | (4.354) |
| Accounts receivable | (3.801) | (8.588) |
| Tax receivables | (1.968) | (1.128) |
| Other receivables | 172 | (414) |
| Accounts payable | 12.028 | (2.700) |
| Income tax payables | 2.163 | (1.894) |
| Other debts | (588) | 3.669 |
| Change in consolidation area / extraordinary events | ||
| Cash flow generated by operating activity | (1.469) | (5.655) |
| Investment activity | ||
| Tangible assets | (9.399) | (352) |
| Intangible assets | (219) | (328) |
| Equity investments, securities and other financial assets | 44 | (1.428) |
| Loan receivables | 150 | 321 |
| Change in consolidation area / extraordinary events | ||
| Cash flow generated by investment activity | (9.425) | (1.787) |
| Financing activity | ||
| Non current financial liabilities | ||
| Current financial liabilities | 293 | 2.218 |
| Dividends paid | (3.726) | (1.376) |
| Change in consolidation area / extraordinary events | (8.434) | (8.479) |
| Cash flow generated by financing activity | (11.867) | (7.637) |
| Change in cumulative translation adjustment reserve and other no monetary changes | 708 | (578) |
| Increase/(decrease) in cash and cash equivalents | (22.052) | (15.657) |
| Cash and cash equivalents at the beginning of the financial period | 97.351 | 97.589 |
| Cash and cash equivalents at the end of the financial period | 75.299 | 81.932 |
The El.En. Group uses some alternative performance indicators that are not identified as IFRS accounting measures, in order to better assess the Group's performance. Therefore criteria of determination applied by the group may not be homogeneous with that adopted by other groups and the value obtained may not be comparable.
These alternative performance indicators, determined in accordance with the Guidelines on Alternative Performance Indicators issued by ESMA / 2015/1415 and adopted by CONSOB with communication no. 92543 of December 3, 2015, refer only to the performance of the accounting period covered by this release and the periods to be compared.
The Group uses the following alternative performance indicators to evaluate the financial performance:
The Group uses as alternative performance indicators to evaluate their ability to cope with financial obligations:
| Fine Comunicato n.0481-40 | Numero di Pagine: 10 |
|---|---|
| --------------------------- | ---------------------- |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.